Association azacitidine et ivosidenib : un nouveau standard de traitement ? Réf. HematoStat.net ; 2(7) : U14 - Montesinos P, Recher C, Vives S, Zarzycka E, Wang J, Bertani G, et al. Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid ...
Réf. :HematoStat.net ; 2 (6) : R51 Lagerlöf I, Fohlin H, Enblad G, Glimelius B, Goldkuhl C, Palma M, et al. Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage […]
Réf. :HematoStat.net ; 2 (6) : R50 Mascarenhas J, Kosiorek HE, Prchal JT, Rambaldi A, Berenzon D, Yacoub A, et al. A randomized phase 3 trial of interferon-α vs hydroxyurea […]
Réf. :HematoStat.net ; 2 (6) : R49 Dodero A, Guidetti A, Marino F, Tucci A, Barretta F, Re A, et al. Dose-adjusted EPOCH and rituximab for the treatment of double […]
Réf. :HematoStat.net ; 2 (6) : R48 Ram R, Grisariu S, Shargian-Alon L, Amit O, Bar-On Y, Stepensky P, et al. Toxicity and efficacy of chimeric antigen receptor T-cell therapy […]
Réf. :HematoStat.net ; 2 (6) : R47 Kuter DJ, Efraim M, Mayer J, Trněný M, McDonald V, Bird R, et al. Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia. N […]
Réf. :HematoStat.net ; 2 (6) : R46 Bachy E, Houot R, Feugier P, Bouabdallah K, Bouabdallah R, Virelizier EN, et al. Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma […]
Réf. :HematoStat.net ; 2 (6) : R45 de Tute RM, Pawlyn C, Cairns DA, Davies FE, Menzies T, Rawstron A, et al. Minimal Residual Disease After Autologous Stem-Cell Transplant for […]
editor’s pick
latest video
news via inbox
Nulla turp dis cursus. Integer liberos euismod pretium faucibua